hotspot -WSS

hotspot

author：Wikipedia 2025-09-29 22:37:30 - browse：57286

Sammy Kimball for STAT

Is Wegovy really a brain drug? Which Alzheimer’s disease treatment works best? And what’s the point of Threads?

We cover all that and more this week on “The Readout LOUD,” STAT’s biotech podcast. Our colleague Megan Molteni joins us to explain the evolving science suggesting products like Wegovy are less weight loss drugs than treatments for human desire. We also explain why this summer is shaping up to be a pivotal moment for the treatment of Alzheimer’s and discuss our befuddlement with the latest social media platform.

For more on what we cover, here’s the story on GLP-1 drugs and the brain; here’s the latest on Leqembi; here’s where you can find episodes of Color Code; and here’s where you can subscribe to the First Opinion Podcast.

Be sure to sign up on Apple Podcasts, Spotify, Stitcher, TuneIn, or wherever you get your podcasts.

And if you have any feedback for us — topics to cover, guests to invite, vocal tics to cease — you can email [email protected].

Previous article： In age of alternative facts, a scholarly course on calling out crap
Next article： Childbirth

hotspot

WSS

BioAge raises $170M for combination therapy with Zepbound

What we’ve learned from the Aduhelm mess

The dental labor crisis is a moment of opportunity

'Revelatory' study finds a smoking impact that remains after quitting

To avoid data mishandling cases, universities eye AI and other tools

Akili, maker of video game for ADHD, to be acquired for 34 million

Wikipedia

hotspot

leisure time

Jerome Adams on the need for new antivirals for Covid

Key House Republican on health care plans exit from Congress

Guidelines to prevent youth baseball injuries need more muscle

Gilead acquiring CymaBay and its liver disease drug for $4.3 billion

Hepatitis C has a cure — but many Americans still lack access to it

Medical mystery: When a cough is not just a cough

What does generative AI mean for health care? We asked experts

A disappointing year of Humira biosimilars

Medicare details structure of new drug price negotiation program

BioAge raises $170M for combination therapy with Zepbound

hotspot

Adam's Biotech Scorecard: Do Sarepta's exon

How digital tools helped lower hypertension in marginalized patients

Stigma and the return of syphilis

Vaccine advisory panel ACIP left half staffed by HHS

Readout LOUD podcast: How biotech is using artificial intelligence

How digital tools helped lower hypertension in marginalized patients

leisure time

hotspot

hotspot

explore